Eliksa therapeutics crunchbase
WebNov 1, 2024 · The company engages in regenerative medicine biotechnology with proprietary technology and a robust clinical pipeline in cardiovascular, ocular, wound management, and osteoarthritic indications, enabling clients to get human doses without any side effects. Contact Information Website www.eliksa.com Ownership Status Privately … WebJul 19, 2024 · Eliksa Therapeutics is a biotechnology company developing novel medicines for a range of debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane. Eliksa’s amniotic fluid-derived biologic is a novel, multi-target modulator of inflammation that promotes cell recovery and tissue healing.
Eliksa therapeutics crunchbase
Did you know?
WebThe City of Fawn Creek is located in the State of Kansas. Find directions to Fawn Creek, browse local businesses, landmarks, get current traffic estimates, road conditions, and more. The Fawn Creek time zone is Central Daylight Time which is 6 hours behind Coordinated Universal Time (UTC). Nearby cities include Dearing, Cotton Valley, … WebAlternatives and possible competitors to Advanced Cell Technology may include iTolerance , Eliksa Therapeutics , and NanoLogix. Unlock even more features with Crunchbase Pro Start Your Free Trial
WebEliksa Therapeutics is a venture-backed biotechnology company with a proprietary cGMP production facility and a robust clinical pipeline addressing unmet medical needs in ocular and...
WebNovira is an antiviral drug discovery company launched in 2009 that is focused on the discovery of novel, first-in-class therapeutics for the treatment of HBV and HIV, two global diseases in need... WebJul 26, 2024 · Eliksa Therapeutics has licensed drug candidates developed by U of Utah researchers that target a range of diseases. The start-up has also acquired rights to AmNova, an amniotic membrane allograft for eye illnesses. ... Eliksa was launched through U of Utah’s commercialization arm, the Partners for Innovation, Ventures, Outreach & …
WebSep 29, 2024 · Therapeutics. Headquarters Regions San Francisco Bay Area, West Coast, Western US. Founded Date 2024. Operating Status Active. Last Funding Type Seed. Company Type For Profit. Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology …
WebLegal Name Eliksa Therapeutics, Inc. Company Type For Profit Contact Email [email protected] Phone Number (267) 209-3442 Lists Featuring This Company Great Lakes Medical Companies (Top 10K) 9,598 Number of Organizations • $54.4B Total Funding Amount • 2,809 Number of Investors Track negative feedback in slaWebElios Therapeutics is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product, TLPLDC, is a … itil foundation certyfikatWebLibra Therapeutics has 6 investors including Yonjin Venture and Sante Ventures. How much funding has Libra Therapeutics raised to date? Libra Therapeutics has raised $29M. When was the last funding round for Libra Therapeutics? Libra Therapeutics closed its last funding round on Sep 23, 2024 from a Series A round. Who are Libra … itil foundation co to jestWebOlatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory... negative feedback in the endocrine systemWebEliksa Therapeutics. Business Services · <25 Employees . Eliksa Therapeutics is a company that operates in the Biotechnology industry. It employs 11-20 people and has $1M-$5M of revenue. Read More. Contact itil foundation classesWebAt Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team... itil foundation exam bookingWebEliksa Therapeutics is a biotechnology company developing novel medicines for a range of debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane. OUR PEOPLE Leadership Team Armen Karamanian, MD, PhD Co-Founder & CEO John Phillips, PhD Advisor Jane Hollingsworth Co-Founder & Executive Chairman … itil foundation company